Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and ...

Feb 18 (Reuters) - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ...

Eli Lilly (LLY) stock is in focus as Zepbound succeeds in a late-stage trial for patients with plaque psoriasis. Read more ...

If you’ve ever suffered from common skin conditions like rosacea, eczema or psoriasis, you know how uncomfortable the intense itching, dryness and redness can be. Fortunately, you don’t have to ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

Three-year BE RADIANT results highlight durable bimekizumab benefits in plaque psoriasis, improving PROs and QoL. Read more.

Black patients on Medicaid less likely to use the newer therapies ...

Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and overweight or obesity, according to topline results announced by Eli ...

Patients with psoriasis were associated with significantly lower circulating BDNF levels compared with healthy control individuals.

The Gulliver-Gestalt-Psoriasis Area Severity Estimate (G2-PASE) was developed to address a longstanding challenge in ...